Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$72.27 USD

72.27
3,014,315

-1.40 (-1.90%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $72.22 -0.05 (-0.07%) 4:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings?

Computer Programs (CPSI) is likely to gain from TruBridge platform in fourth-quarter 2018.

BD Gains From Solid Global Base, Headwinds Anticipated

Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.

HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors

HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.

3 Medical Instruments Stocks Likely to Beat Estimates in Q4

Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.

Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?

LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.

Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?

We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.

Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?

Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.

Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?

Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.

Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?

IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.

Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?

Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.

Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?

McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.

AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards?

AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.

What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?

Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.

Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?

ABIOMED (ABMD) is likely to gain from flagship Impella in third-quarter fiscal 2019; positive trends in the CHD markets buoy optimism.

NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y

NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.

What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?

Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.

Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?

Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.

Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally

Solid overseas growth boosts Varian's (VAR) fiscal Q1 results.

PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong

PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.

Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid

Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.

Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?

PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.

Can Overall Growth Fuel Align Technology's (ALGN) Q4 Earnings?

Align Technology (ALGN) is likely to gain from strength in Invisalign space as well as Scanner and Service business in fourth-quarter 2018.

ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio

ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.